High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses
Open Access
- 5 April 2014
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 106, 86-94
- https://doi.org/10.1016/j.antiviral.2014.03.018
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat AgentsPLOS ONE, 2013
- Recombinant Marburg Virus Expressing EGFP Allows Rapid Screening of Virus Growth and Real-time Visualization of Virus SpreadThe Journal of Infectious Diseases, 2011
- Minigenomes, transcription and replication competent virus-like particles and beyond: Reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever virusesAntiviral Research, 2011
- Ebola haemorrhagic feverPublished by Elsevier ,2010
- Basic Residues within the Ebolavirus VP35 Protein Are Required for Its Viral Polymerase Cofactor FunctionJournal of Virology, 2010
- Minigenome-Based Reporter System Suitable for High-Throughput Screening of Compounds Able To Inhibit Ebolavirus Replication and/or TranscriptionAntimicrobial Agents and Chemotherapy, 2010
- Ebola Virus VP35 Antagonizes PKR Activity through Its C-Terminal Interferon Inhibitory DomainJournal of Virology, 2009
- Nucleocapsid formation and RNA synthesis of Marburg virus is dependent on two coiled coil motifs in the nucleoproteinVirology Journal, 2007
- Broad-Spectrum Antiviral Activity of Small Interfering RNA Targeting the Conserved RNA Termini of Lassa VirusAntimicrobial Agents and Chemotherapy, 2007
- Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication CycleAntimicrobial Agents and Chemotherapy, 2006